Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bifidobacterium affects antitumor efficacy of oncolytic adenovirus in a mouse model of melanoma.
Tripodi L, Feola S, Granata I, Whalley T, Passariello M, Capasso C, Coluccino L, Vitale M, Scalia G, Gentile L, De Lorenzo C, Guarracino MR, Castaldo G, D'Argenio V, Szomolay B, Cerullo V, Pastore L. Tripodi L, et al. Among authors: feola s. iScience. 2023 Aug 19;26(10):107668. doi: 10.1016/j.isci.2023.107668. eCollection 2023 Oct 20. iScience. 2023. PMID: 37720092 Free PMC article.
A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma.
Capasso C, Magarkar A, Cervera-Carrascon V, Fusciello M, Feola S, Muller M, Garofalo M, Kuryk L, Tähtinen S, Pastore L, Bunker A, Cerullo V. Capasso C, et al. Among authors: feola s. Oncoimmunology. 2017 May 11;6(9):e1319028. doi: 10.1080/2162402X.2017.1319028. eCollection 2017. Oncoimmunology. 2017. PMID: 28932628 Free PMC article.
Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses.
Ylösmäki E, Malorzo C, Capasso C, Honkasalo O, Fusciello M, Martins B, Ylösmäki L, Louna A, Feola S, Paavilainen H, Peltonen K, Hukkanen V, Viitala T, Cerullo V. Ylösmäki E, et al. Among authors: feola s. Mol Ther. 2018 Sep 5;26(9):2315-2325. doi: 10.1016/j.ymthe.2018.06.008. Epub 2018 Jun 19. Mol Ther. 2018. PMID: 30005865 Free PMC article.
Harnessing therapeutic viruses as a delivery vehicle for RNA-based therapy.
Ylösmäki L, Polini B, Carpi S, Martins B, Smertina E, Feola S, Fusciello M, Peltonen K, Nieri P, Ylösmäki E, Cerullo V. Ylösmäki L, et al. Among authors: feola s. PLoS One. 2019 Oct 23;14(10):e0224072. doi: 10.1371/journal.pone.0224072. eCollection 2019. PLoS One. 2019. PMID: 31644552 Free PMC article.
Artificially cloaked viral nanovaccine for cancer immunotherapy.
Fusciello M, Fontana F, Tähtinen S, Capasso C, Feola S, Martins B, Chiaro J, Peltonen K, Ylösmäki L, Ylösmäki E, Hamdan F, Kari OK, Ndika J, Alenius H, Urtti A, Hirvonen JT, Santos HA, Cerullo V. Fusciello M, et al. Among authors: feola s. Nat Commun. 2019 Dec 17;10(1):5747. doi: 10.1038/s41467-019-13744-8. Nat Commun. 2019. PMID: 31848338 Free PMC article.
Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy.
Tähtinen S, Feola S, Capasso C, Laustio N, Groeneveldt C, Ylösmäki EO, Ylösmäki L, Martins B, Fusciello M, Medeot M, Tagliamonte M, Chiaro J, Hamdan F, Peltonen K, Ranki T, Buonaguro L, Cerullo V. Tähtinen S, et al. Among authors: feola s. Cancer Res. 2020 Jun 15;80(12):2575-2585. doi: 10.1158/0008-5472.CAN-19-2062. Epub 2020 Feb 27. Cancer Res. 2020. PMID: 32107211
35 results